Search results for "rpoS"

showing 10 items of 512 documents

Repurposing of artemisinin-type drugs for the treatment of acute leukemia.

2020

Cancer treatment represents an unmet challenge due to the development of drug resistance and severe side effects of chemotherapy. Artemisinin (ARS)-type compounds exhibit excellent antimalarial effects with few side effects and drug-resistance. ARS and its derivatives were also reported to act against various tumor types in vitro and in vivo, including acute leukemia. Therefore, ARS-type compounds may be exquisitely suitable for repurposing in leukemia treatment. To provide comprehensive clues of ARS and its derivatives for acute leukemia treatment, their molecular mechanisms are discussed in this review. Five monomeric molecules and 72 dimers, trimers and hybrids based on the ARS scaffold …

0301 basic medicineCancer Researchmedicine.medical_treatmentAntineoplastic AgentsDrug resistancePharmacology03 medical and health sciencesAntimalarials0302 clinical medicineIn vivoNeoplasmsDrug DiscoverymedicineAnimalsHumansArtemisininRepurposingChemotherapyAcute leukemiabusiness.industryDrug Repositioningmedicine.diseaseIn vitroArtemisininsLeukemia030104 developmental biology030220 oncology & carcinogenesisbusinessmedicine.drugSeminars in cancer biology
researchProduct

Repurposing of Drugs Targeting YAP-TEAD Functions

2018

Drug repurposing is a fast and consolidated approach for the research of new active compounds bypassing the long streamline of the drug discovery process. Several drugs in clinical practice have been reported for modulating the major Hippo pathway’s terminal effectors, namely YAP (Yes1-associated protein), TAZ (transcriptional co-activator with PDZ-binding motif) and TEAD (transcriptional enhanced associate domains), which are directly involved in the regulation of cell growth and tissue homeostasis. Since this pathway is known to have many cross-talking phenomena with cell signaling pathways, many efforts have been made to understand its importance in oncology. Moreover, this could be rele…

0301 basic medicineCell signalingCell signalingCancer ResearchProtein-protein interactionsHippo pathwayDrug repurposingprotein-protein interactionsComputational biologyReviewBiologylcsh:RC254-28203 medical and health sciencesYAP-TEAD disruptioncell signalingRepurposingTissue homeostasisHippo signaling pathwaydrug repurposingEffectorCell growthDrug discoveryYap-tead disruptionlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensDrug repositioning030104 developmental biologyOncologyCell signaling; Drug repurposing; Hippo pathway; Protein-protein interactions; Yap-tead disruption; Oncology; Cancer ResearchCancers
researchProduct

Fishing anti-inflammatories from known drugs: In silico repurposing, design, synthesis and biological evaluation of bisacodyl analogues

2017

Herein is described in silico repositioning, design, synthesis, biological evaluation and structure-activity relationship (SAR) of an original class of anti-inflammatory agents based on a polyaromatic pharmacophore structurally related to bisacodyl (BSL) drug used in therapeutic as laxative. We describe the potential of TOMOCOMD-CARDD methods to find out new anti-inflammatory drug-like agents from a diverse series of compounds using the total and local atom based bilinear indices as molecular descriptors. The models obtained were validated by biological studies, identifying BSL as the first anti-inflammatory lead-like using in silico repurposing from commercially available drugs. Several bi…

0301 basic medicineDrugBisacodylAnti-inflammatory databasemedia_common.quotation_subjectIn silico[CHIM.THER]Chemical Sciences/Medicinal Chemistry03 medical and health sciencesIn vivoMolecular descriptorDrug DiscoveryDiarylmethylpyridinesmedicine[CHIM.CRIS]Chemical Sciences/CristallographyBisacodylRepurposingComputingMilieux_MISCELLANEOUSmedia_commonAnti-inflammatory assayChemistry[CHIM.ORGA]Chemical Sciences/Organic chemistryGeneral MedicineCombinatorial chemistry[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM]3. Good health030104 developmental biologyMechanism of actionAtom-based bilinear indicesmedicine.symptomPharmacophoreTOMOCOMD-CARDD SoftwareRepurposingmedicine.drug
researchProduct

Drugs Polypharmacology by in Silico Methods: New Opportunities in Drug Discovery

2016

Background Polypharmacology, defined as the modulation of multiple proteins rather than a single target to achieve a desired therapeutic effect, has been gaining increasing attention since 1990s, when industries had to withdraw several drugs due to their adverse effects, leading to permanent injuries or death, with multi-billiondollar legal damages. Therefore, if up to then the "one drug one target" paradigm had seen many researchers interest focused on the identification of selective drugs, with the strong expectation to avoid adverse drug reactions (ADRs), very recently new research strategies resulted more appealing even as attempts to overcome the decline in productivity of the drug dis…

0301 basic medicineDrugPolypharmacologymedia_common.quotation_subjectIn silicoNanotechnology03 medical and health sciencesBiological and chemical databases computational methods Drugs multitarget activity polypharmacology repurposingDrug DiscoveryMedicineHumansComputer SimulationPolypharmacologyRepurposingmedia_commonPharmacologyMolecular Structurebusiness.industryDrug discoveryDrug repositioningIdentification (information)030104 developmental biologyRisk analysis (engineering)businessChemical databaseSoftware
researchProduct

Myotonic dystrophy type 1 drug development: A pipeline toward the market

2021

Highlights • Myotonic dystrophy, a neuromuscular disease, affects at least around half a million people worldwide. • Close to two dozen preclinical and clinical drug development programs active. • Drugs encompass new chemical entities, repurposing, oligonucleotide, and gene therapy. • Tideglusib, mexiletine, and metformin are close to reaching marketing authorization.

0301 basic medicineDrugmedia_common.quotation_subjectMyotonic dystrophyDiseaseBioinformaticsMarketing authorizationMyotonic dystrophy03 medical and health sciences0302 clinical medicineGene therapyDrug DevelopmentDrug DiscoveryMedicineAnimalsHumansAntisense oligonucleotideRepurposingmedia_commonPharmacologybusiness.industryRepurposing drugmedicine.diseaseClinical trialClinical trialDrug repositioning030104 developmental biologyDrug development030220 oncology & carcinogenesisbusinessPost-Screen (Grey)Drug Discovery Today
researchProduct

Enhanced Antibacterial Activity of Repurposed Mitomycin C and Imipenem in Combination with the Lytic Phage vB_KpnM-VAC13 against Clinical Isolates of…

2021

Study Group on Mechanisms of Action and Resistance to Antimicrobials (GEMARA) on behalf of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

0301 basic medicineImipenemKlebsiella pneumoniaemedicine.drug_classMitomycin030106 microbiologyAntibioticsResistanceDrug repurposingMicrobial Sensitivity TestsBacteriophage therapybeta-LactamasesMicrobiologyPersistence03 medical and health sciencesMechanisms of Resistancemedicinepolycyclic compoundsHumansPharmacology (medical)BacteriophagesPathogenhealth care economics and organizationsPharmacologybiologyMitomycin CBroth microdilutionbiochemical phenomena metabolism and nutritionbiology.organism_classificationAntimicrobialhumanitiesAnti-Bacterial AgentsKlebsiella InfectionsSynergyImipenemKlebsiella pneumoniae030104 developmental biologyInfectious DiseasesLytic cyclemedicine.drugAntimicrobial agents and chemotherapy
researchProduct

Opportunities and challenges for drug development: public-private partnerships, adaptive designs and big data

2016

Drug development faces the double challenge of increasing costs and increasing pressure on pricing. To avoid that lack of perceived commercial perspective will leave existing medical needs unmet, pharmaceutical companies and many other stakeholders are discussing ways to improve the efficiency of drug Research and Development. Based on an international symposium organized by the Medical School of the University of Duisburg-Essen (Germany) and held in January 2016, we discuss the opportunities and challenges of three specific areas, i.e., public-private partnerships, adaptive designs and big data. Public-private partnerships come in many different forms with regard to scope, duration and typ…

0301 basic medicineLeverage (finance)Big dataMedizinReviewAppropriate useadaptive trial design03 medical and health sciencesDrug DevelopmentInformed consentinvestigator-initiated studiesbig dataPharmacology (medical)RepurposingPharmacologyInformed Consentbusiness.industryManagement sciencelcsh:RM1-950Public relationsEuphemismpublic-private partnershipPublic–private partnership030104 developmental biologylcsh:Therapeutics. PharmacologyDrug developmentPrivacyBusinesspublic–private partnershipFrontiers in Pharmacology
researchProduct

Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma

2021

A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of androgen receptor pathway. Therefore, effective drugs against both CRPC and NEPC are needed. We have previously described a dual role of mast cells (MCs) in prostate cancer, being capable to promote adenocarcinoma but also to restrain NEPC. This finding suggests that a molecule targeting both MCs and NEPC cells could be effective against prostate cancer. Using an in silico drug repurposing approach, here we identify the antiepileptic drug levetiracetam as a potential candidate for this purpose. We found that the protein…

0301 basic medicineMaleLevetiracetammast cellsneuroendocrine differentiationNeuroendocrine differentiationCell DegranulationAndrogen deprivation therapyProstate cancer0302 clinical medicineTumor Cells CulturedImmunology and AllergySV2AOriginal ResearchMembrane Glycoproteinsdrug repurposingCell Differentiationprostate cancerGene Expression Regulation NeoplasticMatrix Metalloproteinase 9030220 oncology & carcinogenesisAdenocarcinomaAnticonvulsantsLevetiracetammedicine.druglcsh:Immunologic diseases. AllergyImmunologyAntineoplastic AgentsMice TransgenicNerve Tissue Proteins03 medical and health sciencesmedicineAnimalsHumanstumor microenvironmentmouse modelsHigh-grade prostatic intraepithelial neoplasiadrug repurposing; mast cells; mouse models; neuroendocrine differentiation; prostate cancer; tumor microenvironmentCell Proliferationbusiness.industryDrug RepositioningProstatic NeoplasmsNeoplasms Experimentalmedicine.diseaseCarcinoma Neuroendocrinedrug repurposing mast cells mouse models neuroendocrine differentiation prostate cancer tumor microenvironmentAndrogen receptorMice Inbred C57BL030104 developmental biologyCancer researchlcsh:RC581-607business
researchProduct

Influencia del aceite de coco en enfermos de alzhéimer a nivel cognitivo.

2017

Resumen Introducción: la enfermedad de Alzheimer es a día de hoy la demencia neurodegenerativa con mayor prevalencia en el primer mundo. Este hecho, unido a la falta de tratamiento farmacológico que cure la enfermedad, hace que se estudien nuevas estrategias terapéuticas no farmacológicas como es la administración de nutrientes. En este sentido, destaca la posible influencia del aceite de coco como fuente energética alternativa, capaz de frenar la muerte neuronal que se produce de modo progresivo en esta enfermedad. Objetivos: valorar el impacto del aceite de coco a nivel cognitivo en pacientes de alzhéimer, y concretamente en las áreas de orientación, lenguaje-construcción, fijación, cálcu…

0301 basic medicineNutrition and DieteticsPhilosophyCuerpos cetónicosMedicine (miscellaneous)Trastorns de la cognició en la vellesaTriglicéridosAceite de coco03 medical and health sciences030104 developmental biology0302 clinical medicineHumanitiesEnfermedad de Alzhéimer030217 neurology & neurosurgery
researchProduct

Genomic landscape analyses in cervical carcinoma and consequences for treatment.

2020

Where we are on the road to ‘tailor-made’ precision medicine for drug-resistant cervical carcinoma? We explored studies about analyses of viral and human genomes, epigenomes and transcriptomes, DNA mutation analyses, their importance in detecting HPV sequences, mechanisms of drug resistance to established and targeted therapies with small molecule or therapeutic antibodies, to radiosensitivity and to chemoradiotherapy. The value of repurposing of old drugs initially approved for other disease indications and now considered for cervix cancer therapy is also discussed. The microbiome influences drug response and survival too. HPV genomic integration sites were less significant. Nomograms (Lee…

0301 basic medicineOncologymedicine.medical_specialtyUterine Cervical NeoplasmsDiseaseDrug resistance030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineAnimalsHumansMicrobiomeCervixPapillomaviridaeRepurposingPharmacologybusiness.industryDNAGenomicsPrecision medicinePrognosis030104 developmental biologymedicine.anatomical_structureHuman genomeFemalebusinessChemoradiotherapyCurrent opinion in pharmacology
researchProduct